ストックスクリーナーアプリを入手
14.31
0.06%
-0.0215
前日終値:
$14.33
開ける：
$14.5
24時間の取引高:
239.05K
Relative Volume:
0.22
時価総額：
$872.36M
収益：
$10.00M
当期純損益:
$-113.63M
株価収益率:
-7.8044
EPS:
-1.8334
ネットキャッシュフロー:
$-83.28M
1週間 パフォーマンス:
+1.50%
1か月 パフォーマンス:
-4.14%
6か月 パフォーマンス:
-50.03%
1年 パフォーマンス:
-43.92%
1日の値動き範囲:
$14.20
$14.59
1週間の範囲:
$14.03
$14.83
52週間の値動き範囲:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
名前
Janux Therapeutics Inc
セクター
電話
(858) 751-4493
住所
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.31 | 873.58M | 10.00M | -113.63M | -83.28M | -1.8334 |
VRTX
Vertex Pharmaceuticals Inc
|
424.72 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.69 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.25 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.32 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.11 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | ダウングレード | Barclays | Overweight → Underweight |
| 2026-04-15 | ダウングレード | UBS | Buy → Neutral |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-10 | 開始されました | Stifel | Buy |
| 2025-09-10 | 開始されました | Truist | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-07-11 | 開始されました | Raymond James | Outperform |
| 2024-12-03 | 繰り返されました | BTIG Research | Buy |
| 2024-12-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-22 | 開始されました | Leerink Partners | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Perform |
| 2024-03-21 | 開始されました | BTIG Research | Buy |
| 2024-03-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 開始されました | Wedbush | Outperform |
| 2022-11-14 | 開始されました | William Blair | Outperform |
すべてを表示
Janux Therapeutics Inc (JANX) 最新ニュース
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking Alpha
EX-99.1 - SEC.gov
Janux Therapeutics halts early stage cancer program in 'prudent' move - MSN
JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA) - The Globe and Mail
Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors - simplywall.st
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Point72 affiliates hold 3.07M Janux shares (JANX) — 5.0% stake - Stock Titan
Janux Therapeutics | SCHEDULE 13G: Others - Moomoo
Point72 (NYSE: JANX) entities report 3.07M shares, 5.0% ownership - Stock Titan
Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $68 - Moomoo
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $24 to $68 - Moomoo
Janux ends development of tumor activated T cell engager asset - MSN
Janux Therapeutics, Inc. Files 8-K Report with SEC: Company Information and Key Disclosures (April 28, 2026) - Minichart
Janux Therapeutics Adjusts Board Class Structure for Director - TipRanks
JonesTrading Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $28 - Moomoo
Janux Therapeutics (NASDAQ: JANX) moves Dobmeier to Class II seat - Stock Titan
Janux Therapeutics | ARS: Annual Report to Security Holders - Moomoo
[ARS] Janux Therapeutics, Inc. SEC Filing - Stock Titan
Janux Therapeutics (JANX) sets 2026 virtual meeting, board elections and pay vote - Stock Titan
JonesTrading Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
BofA cuts Janux Therapeutics stock price target on pipeline changes By Investing.com - Investing.com Canada
Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move - Benzinga
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - BioSpace
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN
Barclays downgrades Janux Therapeutics (JANX) - MSN
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Janux to Halt Development of Cancer Drug Candidate JANX008 - marketscreener.com
Janux discontinues EGFR-targeted cancer therapy development By Investing.com - Investing.com Canada
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Janux Therapeutics Announces Collaboration and Exclusive Worldwid - The National Law Review
Janux Therapeutics Inc. (JANX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Janux Therapeutics Inc (JANX) News, Articles, Events & Latest Updates - Stocktwits
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
H.C. Wainwright reiterates Janux Therapeutics stock rating at buy By Investing.com - Investing.com Canada
(JANX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Barclays Downgrades Janux Therapeutics(JANX.US) to Sell Rating, Cuts Target Price to $14 - Moomoo
Barclays Downgrades Janux Therapeutics to Underweight From Overweight, Adjusts Price Target to $14 From $29 - marketscreener.com
Barclays cuts Janux Therapeutics stock rating on near-term concerns By Investing.com - Investing.com Canada
HC Wainwright & Co. Reiterates Janux Therapeutics (JANX) Buy Recommendation - MSN
Janux is a new Buy at Truist ahead of catalyst rich H2 - MSN
Janux Therapeutics Inc (JANX) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):